Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adaptive B cell responses in rituximab-treated diffuse large B cell lymphoma patients during complete remission.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine - 1 Jan 2016

Cha Zhanshan, Li Chen, Zang Yan, Gu Haihui, Guo Huijun, Li Jinqi, Fang Yuan, Petersen Thomas F, Li Jing, Karas Richard O, Hamilton Michele L, Qian Baohua

Abstract excerpt

Rituximab is a chimeric monoclonal antibody directed against the CD20 antigen. Treatment using rituximab in combination with chemotherapy has dramatically improved overall survival rate of diffuse large B cell lymphoma (DLBCL). Since rituximab can deplete both lymphoma B cells and normal B cells, how rituximab-treatment affects normal B cell function in DLBCL patients under remission is unclear. Here, we examined...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD19
Share to B-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Enzyme-Linked Immunosorbent Assay

Share to Flow Cytometry

Share to Immunoglobulin G

Share to Lymphoma, Large B-Cell, Diffuse

Share to Remission Induction

Share to Rituximab

Source

Identifiers

PMID: 26254098
DOI: 10.1007/s13277-015-3872-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adaptive B cell responses in rituximab-treated diffuse large B cell lymphoma patients during complete remission.PMID 26254098Read ↗

Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment.Semantic proximity Read ↗

Depletion of functionally active CD20+ T cells by rituximab treatment.Semantic proximity Read ↗

Rituximab resistance.Semantic proximity Read ↗

Single-cell level characterization of B cell depletion and repopulation following rituximab in systemic lupus erythematosusSemantic proximity Read ↗

In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells.Semantic proximity Read ↗

Specific induction of double negative B cells during protective and pathogenic immune responsesSemantic proximity Read ↗

B cell heterogeneity in human tuberculosis highlights compartment-specific phenotype and putative functional rolesSemantic proximity Read ↗

Specific Induction of Double Negative B Cells During Protective and Pathogenic Immune Responses.Semantic proximity Read ↗

Positive and negative functions of B lymphocytes in tumorsSemantic proximity Read ↗

PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro.Semantic proximity Read ↗

Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-Azacitidine against diffuse large B-cell lymphomaSemantic proximity Read ↗

B cell heterogeneity in human tuberculosis highlights compartment-specific phenotype and functional roles.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.